The clinical significance of anti-müllerian hormone evaluation in gynecological endocrinology

Hormones

Volumn 10, Issue 2, 2011, Pages 95-103

  Karkanaki, Artemis ^a   Vosnakis, Christos ^a   Panidis, Dimitrios ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Anti m llerian hormone; Assisted reproduction techniques; Obesity; Ovarian aging; PCOS; Tumor marker

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ESTRADIOL; FOLLITROPIN; INHIBIN B; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; TESTOSTERONE;

AGING; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; FERTILIZATION IN VITRO; GRANULOSA CELL TUMOR; GYNECOLOGICAL EXAMINATION; HORMONE DETERMINATION; HUMAN; INFERTILITY THERAPY; LOW CALORY DIET; MENOPAUSE; MENSTRUAL CYCLE; NONHUMAN; OBESITY; OVARIAN RESERVE; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PREDICTION; PROGNOSIS; REVIEW; WEIGHT REDUCTION;

EID: 79959221132     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.14310/horm.2002.1299     Document Type: Review

References (83)

1. Cate RL, Mattaliano RJ, Hession, et al, 1986 Isolation of the bovine and human genes for MIS and expression of the human gene in animal cells. Cell 45: 685-698.
2. Cohen-Haguenauer O, Picard Mattei JY, Mattei MG, et al, 1987 Mapping the gene for anti-Müllerian hormone to the short arm of human chromosome 19. Cytogenet Cell Genet 44: 2-6.
3. La Marca A, Volpe A, 2006 Anti-Müllerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? Clin Endocrinol 64: 603-610.
4. Behringer RR, Finegold MJ, Cate RL, 1994 Müllerian inhibiting substance function during mammalian sexual development. Cell 79: 415-425.
5. Lee MM, Donahoe PK, Hasegawa T, et al, 1996 Müllerian inhibiting substance in humans: normal levels from infancy to adulthood. J Clin Endocrinol 81: 571-576.
6. Cook CL, Siow Y, Taylor S, Fallat M, 2000 Serum Müllerian inhibiting substance levels during normal menstrual cycles. Fertil Steril 73: 859-861.
7. Streuli I, Fraisse T, Chapron C, Bijaoui G, Bischof P, de Ziegler D, 2009 Clinical uses of anti-Müllerian hormone assays: pitfalls and promises. Fertil Steril 91: 226-230.
8. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D, 2008 Serum anti-Müllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic steroids. Fertil Steril 90: 395-400.
9. Panidis D, Georgopoulos N, Piouka A, et al, 2010 The impact of oral contraceptives and metformin on Anti-Müllerian hormone serum levels in women with polycystic ovary syndrome. Gynecol Endocrinol 2010 (Epub ahead of print).
10. Mohamed KA, Davies WA, Lashen H, 2006 Anti-Müllerian hormone and pituitary gland activity after prolonged down regulation with gaserelin acetate. Fertil Steril 86: 1515-1517.
11. Seifer D, Golub E, Lambert-Messerilian G, et al, 2009 Variations in serum of Müllerian inhibiting substance between white, black and Hispanic women. Fertil Steril 92: 1674-1678.
12. Visser J, de Jong F, Laven J, Themen A, 2006 Anti- Müllerian hormone: a new marker of ovarian function. Reproduction 131: 1-9.
13. Durlinger AL, Kramer P, Karels B, et al, 1999 Control of primordial follicle recruitment by anti-Müllerian hormone in the mouse ovary. Endocrinology 140: 5789-5796.
14. McGee EA, Hsuesh AJ 2000 Initial and cyclic recruitment of ovarian follicles. Endocr Rev 21: 200-214.
15. Baarends WM, Uilenbroek JT, Kramer P, Hoogebrugge JW, van Leeuwen EC, Themmen AP, 1995 Anti-Müllerian hormone and AMH type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the oestrous cycle and gonadotrophin induced follicle growth. Endocrinology 136: 4951-4962.
16. Shi J, Yoshimo Y, Oshuga Y, et al, 2009 Bone morhogenetic protien-6 stimulates gene expression of follicle stimulating hormone receptor, inhibin/activin β subunit and anti-Müllerian hormone in human granulose cells. Fertil Steril 92: 1794-8.
17. Long WQ, Ranchin V, Pautier P, et al, 2000 Detection of minimal levels of anti-Müllerian hormone during follow up patients with ovarian granulosa cell tumor by means of a highly sensitive immunosorbent assay. J Clin Endocrinol Metab 85: 540-544.
18. Bersinger NA, Winder D, Birkhauser MH, Guibourdenche J, 2007 Measurement of anti-Müllerian hormone by Beckman Coulter ELISA and DSL ELISA in assisted reproduction: differences between serum and follicular fluid. Clin Chim Acta 384: 174-175.
19. de Vet A, Laven JS, de Jong F, Themmen A, Fauser BC, 2002 Anti- Müllerian hormone serum levels: a putative marker for ovarian aging. Fertil Steril 77: 357-362.
20. Franchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J, 2003 Serum Anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 18: 323-327.
21. van Rooij IA, Tonkelaar I, Broekmans FJ, et al, 2004 Anti-Müllerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 11: 601-606.
22. Singer T, Barad D, Weghofer A, Gleicher N, 2009 Correlation of anti-Müllerian hormone and baseline follicle stimulating hormone levels. Fertil Steril 91: 2616-2619.
23. Georgopoulos N, Saltamavros A, Decavalas G, Piouka A, Katsikis I, Panidis D, 2010 Serum AMH, FSH, and LH levels in PCOS. Fertil Steril 93: e13.
24. Lie Fong S, Lugtenburg PJ, Schipper I, et al, 2008 Anti-Müllerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod 23: 674-678.
25. Loverro G, Guarini A, Di Nero E, Giacomantonio L, Lavopa C, Liso V, 2007 Ovarian function after cancer treatment in young women affected by Hodgkin disease. Hematology 12: 141-147.
26. La Marca A, Sighinolfi G, Radi D, et al, 2010 Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 16: 113-130.
27. Al-Qahtami A, Groome N, 2006 Anti-Müllerian hormone: Cinderella finds new admirers. J Clin Endocrinol Metab 91: 3760-3762.
28. Broer S, Mol BW, Dolleman M, Fauser B, Broekmans JM, 2010 The role of anti-Müllerian hormone assessment in assisted reproductive technology outcome. Curr Opin Obstet Gynecol 22: 193-201.
29. Nakhuda GS, Chu MC, Wang J, Sauer M, Lobo RA, 2006 Elevated serum MIS levels may be a marker for ovarian hyperstimulation syndrome in normal women undergoing IVF. Fertil Steril 85: 1541-1543.
30. Nelson SM, Yates RW, Lyall H, et al, 2009 Anti-Müllerian hormone-based approach to controlled ovarian stimulation for assisted conception. Hum Reprod 24: 867-875.
31. Broekmans FJ, Kwee J, Hendriks DJ, 2006 A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 12: 685-718.
32. Fanchin R, Mendez Lozano DH, Frydman N, 2007 Anti-Müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab 92: 1796-1802.
33. Wunder DM, Guibourdenche J, Birkhauser MH, Bersinger NA, 2008 Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injecton. Fertil Steril 90: 2203-2210.
34. Orhan B, Li Q, Carr B, Leader B, Doody K, Doody K, 2010 Repetitive oocyte donaton does not decrease serum anti-Müllerian hormone levels. Fertil Steril 94: 905-912.
35. Rey R, Sabourin JC, Venara M, et al, 2000 Anti-Müllerian hormone is specific marker of sertoli -and granulose-cell origin in gonadal tumors. Hum Pathol 31: 1202-1203.
36. Gustafson ML, Lee MM, Scully RE, et al, 1992 Müllerian inhibiting substance as a marker for ovarian sex cord tumor. New Engl J Med 326: 1820-1826.
37. Rey RA, Lhomme C, Marcillac I, et al, 1996 Anti-Müllerian as a serum marker of granulosa cell tumours of the ovary: comparative study with serum inhibin A and estradiol. Am J Obstet Gynecol 174: 958-965.
38. Rey R, Belville C, Nihoul-Fekete C, et al, 1999 Evaluation of gonadal function in 107 intersex patients by means of serum anti-Müllerian hormone measurement. J Clin Endocrinol Metab 84: 627-631.
39. Dubeau L, 2008 The cell of origin of ovarian epithelial tumours. Lancet Oncol 9: 1191-1197.
40. Masiakos PT, MacLaughlin DT, Maheswaran S, et al, 1999 Human ovarian cancer,cell lines and primary ascites all express the human Müllerian inhibiting substance (MIS) type II receptor, bind and are responsive to MIS. Clin Cancer Res 5: 3488-3499.
41. Stephen AE, Pearsoll LA, Christian BP, Donahoe PK, Vacanti JP, MacLaughlin DT, 2002 Highly purified Müllerian inhibiting substance inhibits human ovarian cancer in vivo. Clin Cancer Res 8: 2640-2646.
42. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004 Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19: 41-47.
43. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R, 1998 Prevalence of the polycystic ovary syndrome in unselected black and white women of the south-eastern United States: a prospective study. J Clin Endocrinol Metab 83: 3078-3082.
44. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al, 1999 A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84: 4006-4011.
45. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF, 2000 A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 85: 2434-2438.
46. Nestler JE, 2008 Metformin for the treatment of the polycystic ovary syndrome. N Engl J Med 358: 47-54.
47. Ehrmann DA, Barnes RB, Rosenfield RL, Cvaghan MK, Imperial J, 1999 Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 22: 141-146.
48. Legro RS, Kunselman AR, Dodson WC, Dunaif A, 1999 Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84: 165-169.
49. Legro RS, Gnatuk CL, Kunselman AR, Dunaif A, 2005 Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. J Clin Endocrinol Metab 90: 3236-3242.
50. Apridonidze T, Essah PA, Luorno MJ, Nestler JE, 2005 Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 90: 1929-1935.
51. Solomon CG, Hu FB, Dunaif A, 2007 Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 87: 2013-2017.
52. Norman RJ, Dewailly D, Legro RS, Hickley T, 2007 Polycystic ovary syndrome. Lancet 370: 685-697.
53. Fallat ME, Siow Y, Marra M, Cook C, Carrillo A, 1997 Müllerian inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome and endometriosis. Fertil Steril 67: 962-965.
54. Cook C, Siow Y, Bremer AG, Fallat ME, 2002 Relation between Müllerian inhibiting substance and other reproductive hormones in untreated women with PCOS and normal women. Fertil Steril 77: 141-146.
55. Pigny P, Merlen E, Robert Y, et al, 2003 Elevated serum level of AMH in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 88: 5957-5962.
56. Pigny P, Jonard S, Robert Y, Dewailly D, 2006 Serum AMH as a surrogate for antral follicle count for definition of polycystic ovary syndrome. J Clin Endocrinol Metab 91: 941-945.
57. Jonard S, Dewailly D, 2004 The follicular excess in polycystic ovaries, due to ovarian hyperandrogenism, may be the culprit for the follicular arrest. Hum Reprod Update 10: 107-117.
58. Grossman M, Nakajima S, Fallat M, Siow Y, 2008 Müllerian inhibiting substance inhibits cytochrome P450 aromatase activity in human granulosa lutein cell culture. Fertil Steril 89: 1364-1370.
59. Hart R, Doherty D, Norman R, et al, 2010 Serum anti-Müllerian hormone (AMH) levels are elevated in adolescent girls with polycystic ovaries and the polycystic ovarian syndrome (PCOS). Feril Steril 94: 1118-1121
60. Pellat L, Hanna L, Brinmat M, Galea R, Brain H, Whitehead S, 2007 Granulosa cell production of anti-Müllerian hormone is increased in polycystic ovaries. J Clin Endocrinol Metab 92: 240-245.
61. Laven JS, Mulders AG, Visser JA, Themmen APN, De Jong FH, Fauser BC, 2004 Anti-Müllerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 89: 318-323.
62. Piouka A, Farmakiotis D, Macut D, Gerou S, Katsikis I, Panidis D, 2009 Anti-Müllerian hormone levels are increased in women with classical PCOS and are negatively influenced by obesity. Am J Physiol Endocrinol Metab 296: E238-243.
63. La Marca A, Orvieto R, Guilini S, Jasonni VM, Volpe A, DeLeo V, 2004 Müllerian inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics. Fertil Steril 82: 970-972.
64. Fleming R, Harborne L, MacLaughlin DT, et al, 2005 Metformin reduces serum Müllerian substance levels in women with PCOS after protracted treatment. Fertil Steril 20: 130-136.
65. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS, 2005 Serum AMH levels remain high until late reproductive age and decrease during metformin treatment in women with polycystic ovary syndrome. Hum Reprod 20: 1820-1826.
66. Carlsen SM, Vanky E, Fleming R, 2009 Anti-Müllerian hormone concentrations in androgen suppressed women with polycystic ovary syndrome. Hum Reprod 24: 1732-1738.
67. Siow Y, Kives S, Hertweek P, Perlman S, Fallat ME, 2005 Serum Müllerian inhibiting substance levels in adolescent girls with normal menstrual cycles or with polycystic ovary syndrome. Fertil Steril 84: 938-944.
68. Sir Petermann T, Conder T, Mliqueo M, Echiburu B, Hitschfeld C, Cristoto N, 2006 Increased anti-Müllerian hormone serum concentrations in prepubertal daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 91: 3105-3109.
69. Zhou R, Bird IM, Dumesic DA, Abbott DH, 2005 Adrenal hyperandrogenism is induced by fetal androgen excess in a rhesus monkey model of polycystic ovary syndrome. J Clin Endocrinol Metab 90: 6630-6637.
70. Rosenfield RL, 2007 Identifying children at risk for polycystic ovary syndrome. J Clin Endocrinol Metab 92: 787-796.
71. Tatone C, Amicarelli F, Carbone MC, et al, 2008 Cellular and molecular aspects of ovarian follicle ageing. Hum Reprod Update 14: 131-142.
72. Victor VM, Rocha M, Bañuls C, et al, 2009 Mitochondrial Complex I Impairment in Leukocytes from Polycystic Ovary Syndrome Patients with Insulin Resistance. J Clin Endocrinol Metab 94: 3505-3512.
73. Diamanti-Kandarakis E, Katsikis I, Piperi C, et al, 2008 Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 69: 634-641.
74. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G, 2005 Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol 62: 37-43.
75. Diamanti-Kandarakis E, Piperi C, Patsouris E, et al, 2007 Immunohistochemical localization of advanced glycation end products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 127: 581-589.
76. Diamanti-Kandarakis E, Piouka A, Livadas S, et al, 2009 Anti-Müllerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol 160: 847-853.
77. Freeman E, Gracia C, Sammel MD, Lin H, Lim LC, Strauss JF 3rd, 2007 Association of anti-Müllerian hormone levels with obesity in late reproductive age women. Fertil Steril 87: 101-106.
78. Seifer D, MacLaughlin D, 2007 Müllerian inhibiting substance is an ovarian growth factor of emerging significance. Fertil Steril 88: 539-546.
79. Panidis D, Farmakiotis D, Rousso D, Katsikis I, Kourtis A, Diamanti-Kandarakis E, 2005 Serum LH levels are markedly increased and significantly correlated with Delta 4-androstendione levels in lean women with polycystic ovary syndrome. Fertil Steril 84: 538-540.
80. Katsikis I, Karkanaki A, Misichronis G, Delkos D, Kandaraki EA, Panidis D, 2011 Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol [Epub ahead of print]
81. Mehri Z, Minkoff H, Feldman J, Macura J, Rodriguez C, Seifer D, 2008 Relationship of bariatric surgery to Müllerian inhibiting substance levels. Fertil Steril 90: 221-224.
82. Moran L, Noakes M, Clifton M, Norman R, 2007 The use of anti-Müllerian hormone in predicting menstrual response after weight loss in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 92: 3796-3802.
83. Thomson RL, Buckley JD, Moran LJ, Noakes M, Clifton RJ, Brinkworth GP, 2009 The effect of weight loss on AMH levels in overweight and obese women with polycystic ovary syndrome and reproductive impairment. Hum Reprod 24: 1976-1981.